Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

about

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

Item

http://www.wikidata.org/entity/Q57111046

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

@en

Optimizing

@nl

type

Item

label

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

@en

Optimizing

@nl

prefLabel

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

@en

Optimizing

@nl

P1476

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

@en

P2093

Heather L McArthur

http://www.w3.org/2001/XMLSchema#string

Reva K Basho

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab containing regimens for early breast cancer

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

P304

1758835918775697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758835918775697

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30034547

http://www.w3.org/2001/XMLSchema#string

P932

6048669

http://www.w3.org/2001/XMLSchema#string

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

about

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932